Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Avenue Therapeutics, Inc. (ATXI)
USD0.25
-0.14 (-35.49%)
US OTC Healthcare Biotechnology
Address
1140 Avenue of the America 10036
New York City, NY, US
New York City, NY, US
CEO
Alexandra MacLean
Website
avenuetx.com
IPO
2017-06-27
CIK 1644963 ISIN US05360L4032
Description
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.25
-0.14 (-35.49%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3.1K
Beta
-0.17
Float Shares
2.83M
Free Float %
86.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -10.02% | -13.32% | +5.98% | +217.93% | -36.51% | -29.89% | +102.94% | -99.40% | -99.99% | -99.99% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
0.25
Low
12.00
+4,698.1%
Consensus
12.00
+4,698.1%
Median
12.00
+4,698.1%
High
12.00
+4,698.1%
DCF (Unlevered)
20.18
+7,967.4%
DCF (Levered)
9.34
+3,636.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-02 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
12.00
+4,698.1%
|
Quality scores
Altman Z-Score
-61.03
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-3.3% Q1'26: +66.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-212.7%
-
EBIT margin Biotechnology: +0.0%-234.1%
-
ROIC Biotechnology: -16.1%— Q1'26: +234.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-75.8% ★ Q1'26: +10.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
est: 28.40M (-100.0%)
|
—
est: 190.70M (-100.0%)
|
1.40M
est: 258.96M (-99.5%)
|
1.40M
1.40M – 1.40M
-99.5% YoY
|
1.40M
1.40M – 1.40M
+0.0% YoY
|
46.51M
46.51M – 46.51M
+3,212.5% YoY
|
| EBITDA |
7.0K
|
-11.70M
est: 114.42M (-110.2%)
|
-3.29M
est: 155.38M (-102.1%)
|
842.4K
842.4K – 842.4K
-99.5% YoY
|
842.4K
842.4K – 842.4K
+0.0% YoY
|
27.90M
27.90M – 27.90M
+3,212.5% YoY
|
| EBIT |
-3.73M
|
-11.70M
est: 114.42M (-110.2%)
|
-3.29M
est: 155.38M (-102.1%)
|
842.4K
842.4K – 842.4K
-99.5% YoY
|
842.4K
842.4K – 842.4K
+0.0% YoY
|
27.90M
27.90M – 27.90M
+3,212.5% YoY
|
| Net Income |
-3.73M
est: -2.91B (+99.9%)
|
-11.65M
est: -19.54M (+40.4%)
|
-2.91M
est: -6.14M (+52.6%)
|
-5.76M
-5.76M – -5.76M
+6.1% YoY
|
-7.01M
-7.01M – -7.01M
-21.7% YoY
|
3.41M
3.41M – 3.41M
+148.7% YoY
|
| SGA |
2.48M
|
4.64M
est: 251.80M (-98.2%)
|
3.65M
est: 341.92M (-98.9%)
|
1.85M
1.85M – 1.85M
-99.5% YoY
|
1.85M
1.85M – 1.85M
+0.0% YoY
|
61.41M
61.41M – 61.41M
+3,212.5% YoY
|
| EPS |
-3.29
est: -225.00 (+98.5%)
|
-0.90
est: -6.24 (+85.6%)
|
-0.93
est: -1.96 (+52.6%)
|
-1.84
-1.84 – -1.84
+6.1% YoY
|
-2.24
-2.24 – -2.24
-21.7% YoY
|
1.09
1.09 – 1.09
+148.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
18
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Fortress Biotech, Inc. 20-5157386 | 3.57M | 33.10% | 3.57M | — | 3.57M | 10.00 | HC | Citizenship or Place of Organization | 2017-10-19 | ↗ |
| 2 | Robert Davidow | 1.93M | 14.50% | 1.02M | — | — | 906.8K | IN | United States | 2023-11-28 | ↗ |
| 3 | Daniel Mack | 1.45M | 7.70% | — | 1.45M | — | — | HC | USA | 2022-02-14 | ↗ |
| 4 | Nantahala Capital Management, LLC | 1.45M | 7.70% | — | 1.45M | — | — | IA | MA | 2022-02-14 | ↗ |
| 5 | Wilmot B. Harkey | 1.45M | 7.70% | — | 1.45M | — | — | HC | USA | 2022-02-14 | ↗ |
| 6 | VANGUARD INDEX FUNDS - VANGUARD TOTAL STOCK MARKET INDEX FUND - 23-2671505 | 838.8K | 5.01% | — | — | — | — | IV | — | 2021-02-08 | ↗ |
| 7 | The Vanguard Group - 23-1945930 | 452.7K | 2.42% | — | — | 446.1K | 6.5K | IA | — | 2022-02-09 | ↗ |
| 8 | CVI Investments, Inc. | 272.7K | 6.60% | — | — | — | 272.7K | CO | Cayman Islands | 2022-10-17 | ↗ |
| 9 | Heights Capital Management, Inc. | 272.7K | 6.60% | — | — | — | 272.7K | CO | Cayman Islands | 2022-10-17 | ↗ |
| 10 | Daniel B. Asher | 216.8K | 4.99% | — | 216.8K | — | 216.8K | HC, IN | Delaware | 2022-10-17 | ↗ |
| 11 | Intracoastal Capital LLC | 216.8K | 4.99% | — | 216.8K | — | 216.8K | OO | Delaware | 2022-10-17 | ↗ |
| 12 | Mitchell P. Kopin | 216.8K | 4.99% | — | 216.8K | — | 216.8K | HC, IN | Delaware | 2022-10-17 | ↗ |
| 13 | Armistice Capital, LLC | 115.0K | 7.21% | — | 115.0K | — | — | IA, OO | Delaware | 2024-11-14 | ↗ |
| 14 | Steven Boyd | 115.0K | 7.21% | — | 115.0K | — | — | HC, IN | Delaware | 2024-11-14 | ↗ |
| 15 | 1 | 9.00 | 11.00% | — | 550.0K | — | 550.0K | IN | Massachusetts | 2019-01-22 | ↗ |
| 16 | CIPLA (EU) LIMITED | — | 0.00% | — | — | — | — | CO | — | 2022-10-19 | ↗ |
| 17 | CIPLA LIMITED | — | 0.00% | — | — | — | — | CO | — | 2022-10-19 | ↗ |
| 18 | INVAGEN PHARMACEUTICALS INC. 20-1420845 | — | 0.00% | — | — | — | — | CO | — | 2022-10-19 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
33.7K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+33,724
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-02 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 111,209 | 0.00 | — | 439,733 | D | ↗ |
| 2025-03-31 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 33,724 | 0.00 | — | 328,524 | D | ↗ |
| 2024-12-31 | Fortress Biotech, Inc. | 10% Owner | — | — | COMMON STOCK, PAR VALUE $0.0001 | 0 | 0.00 | — | 294,800 | D | ↗ |
| 2024-12-02 | Herskowitz Neil | Director | S-Sale | D | COMMON STOCK, PAR VALUE $0.0001 | 23 | 2.00 | 46.00 | 97 | D | ↗ |
| 2024-11-05 | KRANZLER JAY D | Director | S-Sale | D | COMMON STOCK, PAR VALUE $0.0001 | 61 | 2.24 | 136.64 | 559 | D | ↗ |
| 2024-09-30 | KRANZLER JAY D | Director | P-Purchase | A | COMMON STOCK, PAR VALUE $0.0001 | 497 | 2.50 | 1.2K | 620 | D | ↗ |
| 2024-09-27 | KRANZLER JAY D | Director | P-Purchase | A | COMMON STOCK, PAR VALUE $0.0001 | 3 | 2.40 | 7.20 | 123 | D | ↗ |
| 2024-09-23 | ROSENWALD LINDSAY A MD | Director | A-Award | A | Employee stock option (right to buy) | 30,000 | 2.46 | 73.8K | 30,000 | D | ↗ |
| 2024-09-23 | Oltmans Curtis Gale | Director | A-Award | A | Employee stock option (right to buy) | 30,000 | 2.46 | 73.8K | 30,000 | D | ↗ |
| 2024-09-23 | MacLean Alexandra | Director / Officer | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 170,000 | 0.00 | — | 170,000 | D | ↗ |
| 2024-09-23 | KRANZLER JAY D | Director | A-Award | A | Employee stock option (right to buy) | 30,000 | 2.46 | 73.8K | 30,000 | D | ↗ |
| 2024-09-23 | Jin David | Officer | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 65,000 | 0.00 | — | 65,000 | D | ↗ |
| 2024-09-23 | Herskowitz Neil | Director | A-Award | A | Employee stock option (right to buy) | 30,000 | 2.46 | 73.8K | 30,000 | D | ↗ |
| 2024-09-23 | Charles Faith L. | Director | A-Award | A | Employee stock option (right to buy) | 30,000 | 2.46 | 73.8K | 30,000 | D | ↗ |
| 2024-04-16 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 413,507 | 0.00 | — | 3,547,393 | — | ↗ |
| 2024-01-02 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 2,101,496 | 0.00 | — | 3,133,886 | — | ↗ |
| 2023-12-11 | Davidow Robert L | 10% Owner | S-Sale | D | Common Stock | 20,000 | 0.14 | 2.8K | 80,000 | — | ↗ |
| 2023-10-31 | Davidow Robert L | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 945,000 | — | ↗ |
| 2023-09-08 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | Common Stock | 348,675 | 0.72 | 251.0K | 354,318 | — | ↗ |
| 2023-09-08 | Fortress Biotech, Inc. | 10% Owner | P-Purchase | A | Common Stock | 418,410 | 0.72 | 301.3K | 1,032,390 | — | ↗ |
| 2023-06-30 | ROSENWALD LINDSAY A MD | Director | A-Award | A | Employee stock option (right to buy) | 100,000 | 1.14 | 114.0K | 100,000 | — | ↗ |
| 2023-06-30 | Oltmans Curtis Gale | Director | A-Award | A | Employee stock option (right to buy) | 100,000 | 1.14 | 114.0K | 100,000 | — | ↗ |
| 2023-06-30 | KRANZLER JAY D | Director | A-Award | A | Employee stock option (right to buy) | 100,000 | 1.14 | 114.0K | 100,000 | — | ↗ |
| 2023-06-30 | Jin David | Officer | A-Award | A | Employee stock option (right to buy) | 250,000 | 1.14 | 285.0K | 250,000 | — | ↗ |
| 2023-06-30 | Herskowitz Neil | Director | A-Award | A | Employee stock option (right to buy) | 100,000 | 1.14 | 114.0K | 100,000 | — | ↗ |
| 2023-06-30 | Charles Faith L. | Director | A-Award | A | Employee stock option (right to buy) | 100,000 | 1.14 | 114.0K | 100,000 | — | ↗ |
| 2023-06-29 | MacLean Alexandra | Director / Officer | A-Award | A | Employee stock option (right to buy) | 800,000 | 1.14 | 912.0K | 800,000 | — | ↗ |
| 2023-03-31 | Fortress Biotech, Inc. | 10% Owner | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 52,419 | 0.00 | — | 613,980 | — | ↗ |
| 2023-01-03 | Fortress Biotech, Inc. | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 231,316 | 0.00 | — | 561,561 | — | ↗ |
| 2022-12-31 | Fortress Biotech, Inc. | Director | A-Award | A | COMMON STOCK, PAR VALUE $0.0001 | 90,909 | 0.00 | — | 330,245 | — | ↗ |
| 2022-10-11 | InvaGen Pharmaceuticals, Inc. | Director | S-Sale | D | Common Stock, par value $0.0001 per share | 388,888 | 7.71 | 3.00M | 0 | — | ↗ |
| 2022-08-01 | MacLean Alexandra | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-05-16 | Charles Faith L. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-05-11 | Jin David | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-17 | Vazzano Joseph Walter | Officer | A-Award | A | Common Stock | 100,505 | 0.00 | — | 165,757 | — | ↗ |
| 2021-12-17 | Oltmans Curtis Gale | Director | A-Award | A | Common Stock | 49,020 | 0.00 | — | 49,020 | — | ↗ |
| 2021-12-17 | Lu Lucy | Director / Officer | A-Award | A | Common Stock | 411,616 | 0.00 | — | 748,949 | — | ↗ |
| 2021-12-17 | KRANZLER JAY D | Director | A-Award | A | Common Stock | 49,020 | 0.00 | — | 113,683 | — | ↗ |
| 2021-12-17 | Herskowitz Neil | Director | A-Award | A | Common Stock | 49,020 | 0.00 | — | 163,744 | — | ↗ |
| 2021-09-15 | Vazzano Joseph Walter | Officer | S-Sale | D | Common Stock | 7,160 | 1.62 | 11.6K | 65,252 | — | ↗ |
| 2021-05-06 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 2,500 | 3.99 | 10.0K | 134,724 | — | ↗ |
| 2021-04-01 | Oltmans Curtis Gale | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-08-20 | Vazzano Joseph Walter | Officer | S-Sale | D | Common Stock | 3,840 | 12.13 | 46.6K | 57,412 | — | ↗ |
| 2020-06-16 | KRANZLER JAY D | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 84,663 | — | ↗ |
| 2020-06-16 | Herskowitz Neil | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 132,224 | — | ↗ |
| 2020-03-10 | Vazzano Joseph Walter | Officer | P-Purchase | A | Common Stock | 1,889 | 7.94 | 15.0K | 61,252 | — | ↗ |
| 2020-03-09 | Vazzano Joseph Walter | Officer | P-Purchase | A | Common Stock | 100 | 7.97 | 797.00 | 59,363 | — | ↗ |
| 2020-02-27 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 2,400 | 8.20 | 19.7K | 122,224 | — | ↗ |
| 2020-02-26 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 161 | 8.73 | 1.4K | 119,824 | — | ↗ |
| 2020-02-25 | Vazzano Joseph Walter | Officer | P-Purchase | A | Common Stock | 1,200 | 9.09 | 10.9K | 57,863 | — | ↗ |
| 2020-02-25 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 10,000 | 9.31 | 93.1K | 119,663 | — | ↗ |
| 2020-02-12 | Vazzano Joseph Walter | Officer | A-Award | A | Restricted Stock Units | 22,727 | 0.00 | — | 50,505 | — | ↗ |
| 2020-02-12 | Lu Lucy | Director / Officer | A-Award | A | Restricted Stock Units | 110,959 | 0.00 | — | 246,576 | — | ↗ |
| 2019-09-12 | Ingram Elizabeth Garrett | Director | P-Purchase | A | Common Stock | 16,000 | 6.27 | 100.3K | 16,000 | — | ↗ |
| 2019-08-27 | KRANZLER JAY D | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 74,663 | — | ↗ |
| 2019-08-27 | Herskowitz Neil | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 109,663 | — | ↗ |
| 2019-08-09 | Vazzano Joseph Walter | Officer | S-Sale | D | Common Stock | 2,375 | 5.56 | 13.2K | 56,663 | — | ↗ |
| 2019-08-08 | Vazzano Joseph Walter | Officer | S-Sale | D | Common Stock | 2,313 | 5.62 | 13.0K | 59,038 | — | ↗ |
| 2019-08-01 | Ingram Elizabeth Garrett | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-06-18 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 2,000 | 5.83 | 11.7K | 99,663 | — | ↗ |
| 2019-06-17 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 3,000 | 5.88 | 17.6K | 97,663 | — | ↗ |
| 2019-06-03 | Vazzano Joseph Walter | Officer | A-Award | A | Restricted Stock Units | 27,778 | 0.00 | — | 27,778 | — | ↗ |
| 2019-06-03 | Lu Lucy | Director / Officer | A-Award | A | Restricted Stock Units | 135,617 | 0.00 | — | 135,617 | — | ↗ |
| 2019-04-30 | Moore Thomas Gregory | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-04-15 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 1,000 | 4.52 | 4.5K | 94,663 | — | ↗ |
| 2019-03-29 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 1,400 | 5.11 | 7.2K | 93,663 | — | ↗ |
| 2019-03-28 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 600 | 5.11 | 3.1K | 92,263 | — | ↗ |
| 2019-02-25 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 5,000 | 5.46 | 27.3K | 91,663 | — | ↗ |
| 2019-02-08 | Saxena Nishant | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-02-08 | InvaGen Pharmaceuticals, Inc. | — | — | I | Restricted Stock Units | 135,617 | 0.00 | — | 0 | — | ↗ |
| 2019-02-08 | Gogtay Jaideep Ashok | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-02-05 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 1,850 | 5.77 | 10.7K | 86,663 | — | ↗ |
| 2019-02-04 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 7,000 | 5.91 | 41.4K | 84,813 | — | ↗ |
| 2019-01-30 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 650 | 5.91 | 3.8K | 77,813 | — | ↗ |
| 2019-01-29 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 8,553 | 5.91 | 50.5K | 77,163 | — | ↗ |
| 2019-01-28 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 1,447 | 5.84 | 8.5K | 68,610 | — | ↗ |
| 2018-12-10 | Paley Jeffrey | Director | P-Purchase | A | Common Stock | 5,000 | 4.76 | 23.8K | 79,663 | — | ↗ |
| 2018-12-03 | Paley Jeffrey | Director | P-Purchase | A | Common Stock | 10,000 | 5.48 | 54.8K | 74,663 | — | ↗ |
| 2018-08-07 | WEISS MICHAEL S | Director | G-Gift | A | Common Stock | 14,663 | 0.00 | — | 24,663 | — | ↗ |
| 2018-08-07 | Vazzano Joseph Walter | Officer | G-Gift | A | Common Stock | 30,000 | 0.00 | — | 61,351 | — | ↗ |
| 2018-08-07 | SAMAD AKHTAR | Director | G-Gift | A | Common Stock | 14,663 | 0.00 | — | 64,663 | — | ↗ |
| 2018-08-07 | Reines Scott | Officer | G-Gift | A | Common Stock | 10,000 | 0.00 | — | 45,000 | — | ↗ |
| 2018-08-07 | ROSENWALD LINDSAY A MD | Director | G-Gift | A | Common Stock | 14,663 | 0.00 | — | 84,663 | — | ↗ |
| 2018-08-07 | Paley Jeffrey | Director | G-Gift | A | Common Stock | 14,663 | 0.00 | — | 64,663 | — | ↗ |
| 2018-08-07 | Lu Lucy | Director / Officer | G-Gift | A | Common Stock | 250,000 | 0.00 | — | 807,333 | — | ↗ |
| 2018-08-07 | KRANZLER JAY D | Director | G-Gift | A | Common Stock | 14,663 | 0.00 | — | 64,663 | — | ↗ |
| 2018-08-07 | Herskowitz Neil | Director | G-Gift | A | Common Stock | 14,663 | 0.00 | — | 67,163 | — | ↗ |
| 2018-06-28 | Vazzano Joseph Walter | Officer | A-Award | A | Common Stock | 1,351 | 3.66 | 4.9K | 31,351 | — | ↗ |
| 2018-06-14 | Lu Lucy | Director / Officer | A-Award | A | Common Stock | 5,000 | 4.00 | 20.0K | 557,333 | — | ↗ |
| 2018-06-08 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | Common Stock | 5,234 | 4.34 | 22.7K | 70,000 | — | ↗ |
| 2018-06-07 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | Common Stock | 14,800 | 4.32 | 64.0K | 64,766 | — | ↗ |
| 2018-06-06 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | Common Stock | 9,100 | 4.35 | 39.6K | 49,966 | — | ↗ |
| 2018-06-05 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | Common Stock | 8,400 | 4.28 | 35.9K | 40,866 | — | ↗ |
| 2018-06-04 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | Common Stock | 3,800 | 4.19 | 15.9K | 32,466 | — | ↗ |
| 2018-06-01 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | Common Stock | 8,666 | 4.15 | 36.0K | 28,666 | — | ↗ |
| 2018-04-25 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 1,000 | 3.80 | 3.8K | 52,500 | — | ↗ |
| 2017-10-17 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 1,000 | 5.01 | 5.0K | 51,500 | — | ↗ |
| 2017-10-09 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | Common Stock | 1,350 | 5.40 | 7.3K | 20,000 | — | ↗ |
| 2017-10-09 | Herskowitz Neil | Director | P-Purchase | A | Common Stock | 500 | 5.24 | 2.6K | 50,500 | — | ↗ |
| 2017-10-06 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | Common Stock | 2,900 | 5.63 | 16.3K | 18,650 | — | ↗ |
| 2017-10-05 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | Common Stock | 3,550 | 5.60 | 19.9K | 15,750 | — | ↗ |
| 2017-10-04 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | Common Stock | 2,200 | 5.60 | 12.3K | 12,200 | — | ↗ |
| 2017-09-28 | Lu Lucy | Director / Officer | A-Award | A | Common Stock | 4,000 | 5.20 | 20.8K | 552,333 | — | ↗ |
| 2017-08-08 | Vazzano Joseph Walter | Officer | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 30,000 | — | ↗ |
| 2017-03-13 | WEISS MICHAEL S | Director | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2017-03-13 | SAMAD AKHTAR | Director | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2017-03-13 | Reines Scott | Officer | — | D | Common Stock | 0 | 0.00 | — | 35,000 | — | ↗ |
| 2017-03-13 | ROSENWALD LINDSAY A MD | Director | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2017-03-13 | Paley Jeffrey | Director | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2017-03-13 | Lu Lucy | Director / Officer | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 548,333 | — | ↗ |
| 2017-03-13 | KRANZLER JAY D | Director | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2017-03-13 | Herskowitz Neil | Director | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2017-03-13 | Fortress Biotech, Inc. | 10% Owner | — | D | Class A Preferred Stock | 0 | 0.00 | — | 250,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-16.4K
Shares Outstanding
3.29M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Alexandra MacLean Chief Executive Officer | 420.0K | — | 406.3K | — | — | 13.8K | 840.1K | 48.36% | ↗ |
| 2 | 2024 | David Jin Interim Chief Financial Officer and Chief Operating Officer | — | — | 155.4K | — | — | — | 155.4K | 100.00% | ↗ |
| 3 | 2023 | Alexandra MacLean Chief Executive Officer | 400.0K | — | — | 800.0K | — | 13.2K | 1.21M | 65.94% | ↗ |
| 4 | 2023 | David Jin Interim Chief Financial Officer and Chief Operating Officer | — | — | — | 260.0K | — | — | 260.0K | 100.00% | ↗ |
| 5 | 2022 | Lucy Lu Former Chief Executive Officer | 158.7K | — | — | — | 400.0K | 12.2K | 570.9K | 0.00% | ↗ |
| 6 | 2022 | Alexandra MacLean Chief Executive Officer | 153.6K | 120.0K | — | — | 20.0K | 7.0K | 300.5K | 0.00% | ↗ |
| 7 | 2022 | Joseph Vazzano Former Chief Financial Officer | 20.5K | — | — | — | — | 822.00 | 21.3K | 0.00% | ↗ |
| 8 | 2021 | Lucy Lu Chief Executive Officer | 454.6K | — | 382.8K | — | 233.1K | 11.6K | 1.08M | 35.37% | ↗ |
| 9 | 2021 | Lucy Lu Former Chief Executive Officer | 454.6K | 233.1K | 382.8K | — | — | 11.6K | 1.08M | 35.37% | ↗ |
| 10 | 2021 | Joseph Vazzano Chief Financial Officer | 255.7K | — | 93.5K | — | 80.5K | 11.6K | 441.3K | 21.18% | ↗ |
| 11 | 2021 | Joseph Vazzano Former Chief Financial Officer | 255.7K | 80.5K | 93.5K | — | — | 11.6K | 441.3K | 21.18% | ↗ |
| 12 | 2020 | Lucy Lu Chief Executive Officer | 431.6K | — | — | — | — | 11.4K | 443.0K | 0.00% | ↗ |
| 13 | 2020 | Joseph Vazzano Chief Financial Officer | 206.0K | — | — | — | — | 8.9K | 214.9K | 0.00% | ↗ |
| 14 | 2019 | Lucy Lu Chief Executive Officer | 419.1K | — | — | — | 209.5K | 11.4K | 639.8K | 0.00% | ↗ |
| 15 | 2019 | Joseph Vazzano Chief Financial Officer | 198.1K | — | — | — | 50.0K | 10.7K | 258.8K | 0.00% | ↗ |
| 16 | 2018 | Lucy Lu Chief Executive Officer | 406.9K | — | 865.0K | — | 315.3K | 7.5K | 1.59M | 54.24% | ↗ |
| 17 | 2018 | Joseph Vazzano Chief Financial Officer | 175.1K | — | 103.8K | — | 67.9K | 7.8K | 354.5K | 29.28% | ↗ |
| 18 | 2018 | Scott A. Reines Interim Chief Medical Officer | 69.1K | — | 54.0K | — | — | — | 123.1K | 43.86% | ↗ |
| 19 | 2017 | Lucy Lu Chief Executive Officer | 294.9K | 282.6K | 1.46M | — | — | 8.8K | 2.04M | 71.28% | ↗ |
| 20 | 2017 | Joseph Vazzano Chief Financial Officer | 74.8K | 48.6K | 203.1K | — | — | 1.1K | 327.6K | 61.99% | ↗ |
| 21 | 2017 | Joseph Vazzano Vice President of Finance and Corporate Controller | 3.00 | 48.6K | 203.1K | — | — | — | 326.5K | 62.21% | ↗ |
| 22 | 2017 | Scott A. Reines Interim Chief Medical Officer | 38.1K | — | 126.7K | — | — | — | 164.8K | 76.88% | ↗ |
| 23 | 2016 | Lucy Lu Chief Executive Officer | 2.00 | 6.00 | 27.9K | — | — | — | 344.8K | 8.08% | ↗ |
| 24 | 2016 | Scott A. Reines Interim Chief Medical Officer | 4.00 | — | — | — | — | — | 43.2K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alexandra MacLean | Chief Executive Officer & Director | 434.0K | — |
| David Jin | Interim Chief Financial Officer, Chief Operating Officer & Corporate Secretary | — | male |
| Lindsay Allan Rosenwald | Executive Director | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ATXI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
